Shattuck Labs SL-9258 /Anti-PD(L)1 Shows Broadened Anti-Tumor Activity In CPI-Resistant Cancers
Shattuck Labs Inc (NASDAQ:STTK) announced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting, including data from SL-9258 (TIGIT-Fc-LIGHT) and the Company's GADLEN platform. Preclinical data for SL-9258 (TIGIT-Fc-LIGHT), a bispecific fusion protein from its ARC platform, demonstrates that SL-9258 simultaneously provides checkpoint blockade to all tumor-expressed PVR ligands…
Benzinga ·